Building on expertise in materials science, drug development and formulation, the Lyra team has developed a transmucosal therapeutic system. This proprietary platform is designed to enable long-acting, local delivery of medications over an extended period of time, directly targeting tissue deep in the ear, nose and throat (ENT) passages. Lyra’s platform enables a wide range of product applications to provide medicine directly to diseased tissues that are not accessible with conventional therapeutic approaches.
Lyra’s Platform: a Transmucosal Therapeutic System for ENT Diseases
Proprietary Therapeutic Platform
Lyra has a robust global portfolio of intellectual property. These patents cover all aspects of the transmucosal therapeutic system, including controlled drug release and materials science for adaptive applications in biologic environments. All intellectual property protecting the Lyra platform has been developed and is owned by the company.